Navamedic ASA Company Description

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally.

The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics.

It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, malnutrition, and ketogenic diet.

In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women’s health, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson’s disease, urology, and cardiology; and antibiotics.

It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004.

Navamedic ASA was incorporated in 2002 and is based in Oslo, Norway.

Navamedic ASA

Country	Norway
Founded	2002
Industry	Pharmaceutical Preparations
Employees	42
CEO	Kathrine E. Andreassen

Contact Details

Address: Henrik Ibsens gate 100 Oslo, 0255 Norway
Phone	47 67 11 25 40
Website	navamedic.com

Stock Details

Ticker Symbol	N1A
Exchange	Frankfurt Stock Exchange
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	NOK
SIC Code	2834

Key Executives

Name	Position
Kathrine E. Andreassen	Chief Executive Officer
Lars Hjarrand	Chief Financial Officer
Alexander Lidmejer	Chief Operating Officer